Transcriptional modulator ZBED6 affects cell cycle and growth of human colorectal cancer cells by Muhammad Akhtar Ali et al.
Transcriptional modulator ZBED6 affects cell cycle and
growth of human colorectal cancer cells
Muhammad Akhtar Alia,1, Shady Younisb,c,1, Ola Wallermand, Rajesh Guptab, Leif Anderssonb,d,e,1,2,
and Tobias Sjöbloma,1
aScience For Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-751 85 Uppsala, Sweden; bScience for Life
Laboratory, Department of Medical Biochemistry and Microbiology, Uppsala University, SE-751 85 Uppsala, Sweden; cDepartment of Animal Production,
Ain Shams University, Shoubra El-Kheima, 11241 Cairo, Egypt; dDepartment of Animal Breeding and Genetics, Swedish University of Agricultural Sciences,
SE-75007 Uppsala, Sweden; and eDepartment of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M
University, College Station, TX 77843
Contributed by Leif Andersson, May 15, 2015 (sent for review December 10, 2014; reviewed by Jan-Ake Gustafsson)
The transcription factor ZBED6 (zinc finger, BED-type containing 6)
is a repressor of IGF2 whose action impacts development, cell pro-
liferation, and growth in placental mammals. In human colorectal
cancers, IGF2 overexpression is mutually exclusive with somatic
mutations in PI3K signaling components, providing genetic evi-
dence for a role in the PI3K pathway. To understand the role of
ZBED6 in tumorigenesis, we engineered and validated somatic cell
ZBED6 knock-outs in the human colorectal cancer cell lines RKO
and HCT116. Ablation of ZBED6 affected the cell cycle and led to
increased growth rate in RKO cells but reduced growth in HCT116
cells. This striking difference was reflected in the transcriptome
analyses, which revealed enrichment of cell-cycle–related pro-
cesses among differentially expressed genes in both cell lines,
but the direction of change often differed between the cell lines.
ChIP sequencing analyses displayed enrichment of ZBED6 binding
at genes up-regulated in ZBED6-knockout clones, consistent with
the view that ZBED6 modulates gene expression primarily by
repressing transcription. Ten differentially expressed genes were
identified as putative direct gene targets, and their down-regula-
tion by ZBED6 was validated experimentally. Eight of these genes
were linked to the Wnt, Hippo, TGF-β, EGF receptor, or PI3K path-
ways, all involved in colorectal cancer development. The results of
this study show that the effect of ZBED6 on tumor development
depends on the genetic background and the transcriptional state
of its target genes.
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Colorectal cancers (CRCs) are caused by sequential mutationsin driver genes of key cellular systems such as the Wnt,
EGFR/Ras/MAPK, PI3K, TGFB, and TP53 pathways (1). So-
matic mutations in the PI3K pathway members PIK3CA and
PTEN occur late in CRC progression and contribute to increased
tumor cell growth and invasivity (2–4). In CRC, overexpression of
IGF2 is mutually exclusive with activating genomic alterations of
the PI3K pathway genes PIK3CA and PIK3R1 (5). Further, IRS2
overexpression is mutually exclusive with IGF2 overexpression.
The IRS2 gene is frequently amplified in CRCs (5) and encodes a
protein that links IGF1R, a receptor for IGF1 and IGF2, with
PI3K signaling. The importance of this pathway in colorectal tu-
morigenesis motivates studies to understand its regulation better.
The ZBED6 (zinc finger, BED-type containing 6) transcription
factor is a recently discovered negative regulator of IGF2 expression
(6, 7). The intronless ZBED6 gene encodes two N-terminal zinc
finger BED domains (8) and an hAT (hobo-Ac-Tam3) dimerization
domain. Based on its primary structure, ZBED6 belongs to the hAT
transposase family (9). The ZBED6 gene is located in the first in-
tron of ZC3H11A and is transcribed as a composite transcript from
the ZC3H11A promoter. An SNP (rs4951011) located in the
5′ UTR of ZBED6 recently was found to be associated with breast
cancer susceptibility in a genome-wide association study (10). In
pigs, a G-to-A mutation in the highly conserved CpG island in the
third intron of IGF2 was identified as a quantitative trait nucleotide
(QTN) with a large impact on body composition (muscle growth
and fat deposition); mutant animals showed threefold higher IGF2
expression in postnatal muscle (11). ZBED6 was identified as the
nuclear factor specifically binding the wild-type IGF2 sequence but
not the mutated site. ChIP sequencing (ChIP-seq) in mouse C2C12
cells identified more than 1,200 putative ZBED6 target genes, in-
cluding 262 genes encoding transcription factors (6). The most
common human orthologs of mouse ZBED6 target genes are re-
lated to developmental disorders and cancers. ZBED6 silencing
induced IGF2 overexpression, increased cell proliferation, and ac-
celerated wound healing (6) in C2C12 cells.
The importance of IGF2 and the PI3K pathway activation in
cancer, along with the regulatory role of ZBED6 in IGF2 signal-
ing, prompted us to investigate the role of ZBED6 in cancer. To
explore the interaction between ZBED6 and its putative target
genes in human cells, we knocked out ZBED6 by homologous
recombination in HCT116 and RKO CRC cells. Here we report
how this knock-out affects cell growth and gene regulation.
Results
Generation and Validation of ZBED6 Knockout Cell Lines. The
recombinant adeno-associated virus (rAAV) gene-targeting con-
struct was designed to insert a stop codon at position 173 in
ZBED6 by homologous recombination (Fig. 1A). We sequentially
targeted both ZBED6 alleles in the human CRC cell lines HCT116
and RKO (Fig. 1B) and obtained three independent knockout cell
clones for each genetic background. The gene-targeting efficiency
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was higher in HCT116 cells (20%) than in RKO cells (1%). Three
independent ZBED6−/− clones per cell line were selected based on
two criteria: complete loss of ZBED6 protein and intact expression
of the host gene ZC3H11A. In both HCT116 and RKO cell lines,
there were no significant changes in ZC3H11A mRNA expression
between parental cells and ZBED6−/− clones (Table S1). However,
immunoblot analysis using anti-ZBED6 and anti-ZC3H11A anti-
bodies revealed a complete loss of ZBED6 protein that did not
affect the expression of ZC3H11A (Fig. 1C). In the parental cells,
the IGF2 expression level was 250-fold higher in HCT116 cells
than in RKO cells (Fig. 1D, Left). In both isogenic models IGF2
expression was increased in ZBED6−/− clones relative to parental
cells, 1.4-fold in HCT116 cells and threefold in RKO cells (P <
0.05) (Fig. 1D, Right). Thus, the ZBED6−/− knockout cell lines
showed loss of ZBED6 expression and retained ZC3H11A expres-
sion and up-regulation of IGF2 expression relative to parental cells,
but the relative increase in IGF2 expression after ZBED6 si-
lencing differed significantly in the two cell lines (Fig. 1D).
Loss of ZBED6 Has Opposite Effects on Cancer Phenotypes in RKO and
HCT116 Cells. We assessed the effect of ZBED6 on CRC pheno-
types by measuring alterations in growth rate and cell-cycle
regulation. Loss of ZBED6 in the three biological replicates of
HCT116 cells had a growth-inhibitory effect and reduced their
clonogenic survival (Fig. 2A). In contrast, ZBED6 silencing in
RKO cells led to a small but consistent increased growth rate but
had no significant effect on clonogenic survival (Fig. 2B). The
heterozygous clones show a growth phenotype similar to their
corresponding homozygote knockout clone (Fig. S1).
To verify that the increased growth rate seen in RKO cells
indeed was caused by the loss of ZBED6, we performed a rescue
experiment in which we stably expressed mouse Zbed6 in RKO
ZBED6−/− cells. Two independent clones were obtained, and the
expression of full-length AcGFP-Zbed6 was confirmed (Fig. S2A).
The expression of AcGFP-Zbed6 was localized to the nucleus (Fig.
S2B). Although the ZBED6−/− clones grew faster than parental
RKO cells, AcGFP-Zbed6 clones grew at a slower rate than parental
RKO and ZBED6−/− cells (Fig. 2C), and Zbed6 overexpression re-
duced clonogenic survival 2.5-fold compared with the RKO
ZBED6−/− cells (Fig. 2C). To understand the underlying reason for
the increased growth rate of RKO ZBED6−/− cells, we performed
cell-cycle analysis and observed a higher fraction of cells in S-phase
in RKO ZBED6−/− cells than in their parental cells (Fig. 2D).
Our attempts to express mouse Zbed6 stably in HCT116
ZBED6−/− cells failed. Our experience and previously published
0 
1 
2 
3 
Fo
ld
 c
ha
ng
e 
in
 IG
F2 Wild-type
ZBED6-/-
0
100 
200 
300 
RK
O 
HC
T1
16Re
la
tiv
e 
ex
pr
es
si
on
 o
f I
G
F2
3
S.C.
HCT116
RKO
Targeted
+/+ +/- -/- +/- -/--/- +/-
1 2 3 Clone
14
13
Targeted allele
3
11
12
7 8 10
S.C.
11
9
ZBED6 locus
L-ITR R-ITR
HA1 HA2
Gene targeting
construct
WT
RKO HCT116
Parental
ZBED6
ZC3H11A
TBP
Parental
ZBED6-/- clone
1 2 3
ZBED6-/- clone
1 2 3
RK
O 
HC
T1
16
*** **
*
A
B
C
D
Fig. 1. Knock-out of ZBED6 in human HCT116 and RKO CRC cells by rAAV-
mediated homologous recombination. (A) The targeting construct was
designed to replace ZBED6 Q173 by a stop codon. Numbers indicate pri-
mers used in HA amplification (7–10), PCR screening (11 and 12), and Cre-
mediated removal of the resistance marker (13 and 14) (Table S2). L/R-ITR,
left/right inverted terminal repeat; S.C., selection cassette containing
neomycin resistance gene; WT, wild-type allele. (B) PCR detection of tar-
geted ZBED6 alleles in parental (+/+), heterozygous (+/−), and knockout (−/−)
cells in three independent clones each in HCT116 and RKO cells. The size
shift in targeted alleles represents LoxP sequences remaining after Cre-
mediated excision of the resistance marker. (C ) Immunoblot detection of
ZBED6, ZC3H11A, and TBP (loading control) in total cell lysates from pa-
rental cells and knockout clones of RKO and HCT116 cell lines. (D) RT-PCR
analysis of IGF2 expression. (Left) Expression level in parental cell lines
normalized to RKO. (Right) Expression levels in ZBED6−/− clones relative to
the respective parental cell line.
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Fig. 2. ZBED6 ablation alters cell growth in both HCT116 and RKO CRC cells.
(A) Real-time measurements of cell density (mean ± SD) (Left) and clono-
genic survival on plastic (Right) of 1,000 seeded cells of parental HCT116 cells
(black) and ZBED6−/− clones (gray). (B) Real-time measurements of cell
density (mean ± SD) (Left) and clonogenic survival on plastic (Right) of 1,000
seeded cells of parental RKO cells (black) and ZBED6−/− clones (gray). (C, Left)
Real-time measurements of cell density (mean ± SD) for parental RKO cells
(black), and ZBED6− /− AcGFP (gray) and ZBED6− /− AcGFP-Zbed6 (red)
clones. (Right) Clonogenic survival on plastic of 1,000 seeded ZBED6−/−
AcGFP clones (gray and ZBED6−/− AcGFP-Zbed6 #1 and #2 clones (red).
(D) Cell-cycle profile of RKO parental cells (black) and ZBED6−/− clones (gray).
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data (12) indicate that it is more challenging to overexpress
ZBED6 stably than to silence this transcript.
Direct and Indirect Effects of ZBED6 Deletion on the Transcriptome of
CRC Cells. We performed whole-transcriptome analyses (RNA-
seq) using three independent ZBED6−/− clones as biological
replicates for both RKO and HCT116 cell lines (Fig. 3A). Read
alignment with TopHat identified 11,084 genes expressed in
RKO cells at sufficient levels for differential expression (DE)
analysis using Cufflinks. The expression of 2,807 genes was found
to be changed significantly (P < 0.05 after Benjamini–Hochberg
correction for multiple testing), with 1,310 up-regulated and
1,497 down-regulated genes in the ZBED6− /− RKO clones.
Principal component and dendrogram analyses separated the
respective parental cell line from their ZBED6−/− derivatives
(Fig. S3). For HCT116, 2,229 of 11,903 expressed genes were
identified as DE (P < 0.05); 1,378 genes were up-regulated, and
851 genes were down-regulated. Gene ontology (GO) analysis
was performed by comparing DE genes with all expressed genes
as a background and revealed a significant enrichment of genes
related to the regulation of cell proliferation and cell cycle in
both RKO and HCT116 cells (Fig. 3B and Dataset S1). When
the direction of change was taken into account, we found that the
most striking enrichment for cell-cycle–related categories such as
mitosis and M-phase were associated with up-regulated genes in
RKO cells, whereas genes annotated as associated with cell
death and negative regulation of cell proliferation tended to be
up-regulated in HCT116 cells (Fig. S4B). Genes involved in cell
proliferation also appeared to be enriched among down-regu-
lated genes in HCT116 cells (Fig. S4 and Dataset S1). These
patterns of altered transcription are consistent with the striking
difference in phenotypic change after ZBED6 knockout, in
which RKO and HCT116 cells show increased and decreased
proliferation, respectively. Fig. 3C illustrates examples of genes
associated with cell proliferation that showed opposite trends in
RKO and HCT116 cells after ZBED6 knock-out.
Most (87.5%) of the genes identified as expressed in HCT116
cells also were expressed in RKO cells. There was a significant
overlap of DE genes (χ2, d.f. = 1, P < 10−4), with 608 genes in
common. However, there was no consistent direction of DE;
only half had the same direction of change in the two cell lines;
194 were up-regulated and 113 were down-regulated in RKO
and HCT116 ZBED6−/− cells (Fig. S4A). The percentage of
overlapping genes was slightly higher for the up-regulated genes
than for the down-regulated genes (14.9% vs. 12.7%), possibly
because of a repressive effect of ZBED6 at a subset of the DE
genes, similar to its effect at IGF2. To test this notion further, we
used ChIP-seq in parental HCT116 cells to identify genes bound
by ZBED6 in CRC cells (Fig. S5). This analysis gave more than
7,000 peaks with significant ZBED6 enrichment, with 70% oc-
curring within 1 kb of a refGene transcription start site (TSS).
We found ZBED6 sites to be enriched at up-regulated genes
compared with down-regulated genes, and this difference was more
pronounced when only genes showing DE in the two cell lines were
considered (Fig. 3D). This enrichment was caused by a larger number
of genes with strong ZBED6 enrichment among up-regulated
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Fig. 3. Transcriptome analysis of RKO and HCT116 parental cells and ZBED6−/− KO clones. (A) Gene expression as FPKM values in parental versus ZBED6−/−
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genes, with 16 of the shared up-regulated genes (19%) having a
ZBED6 peak with a score above 30 within 1 kb of the TSS,
whereas only 4 (7%) of the down-regulated genes had scores ex-
ceeding 30 (Table 1). These results suggest that ZBED6 is a direct
repressor of several up-regulated genes after ZBED6 silencing.
Validation of Putative Direct ZBED6 Gene Targets. Given the en-
richment of ZBED6 peaks at up-regulated genes and the
established role of ZBED6 as a repressor of IGF2, we selected
for further validation 10 potential direct ZBED6 target genes
[ARL4C, FOSL2, MYBL1, PMEPA1, ROCK2, SGK1, SPTBN1,
TCF7, WWC1, WWTR1) (Table 1)] that (i) were up-regulated ≥1.5-
fold in both RKO and HCT116 ZBED6−/− cells and (ii) had a
strong ZBED6 ChIP-seq peak near the TSS (Fig. 4A and Fig. S5).
We evaluated expression change by quantitative PCR (qPCR) in
both isogenic pairs and observed significant changes for all these
genes in RKO ZBED6−/− cells and for the majority of these genes in
HCT116 ZBED6−/− cells (Fig. 4 B and C). In parallel, we knocked
down the expression of ZBED6 in HCT116 parental cells using
siRNA. Near 50% silencing of ZBED6 expression was obtained,
resulting in alterations in expression similar to those observed in
HCT116 ZBED6−/− cells with statistically significant up-regulation
of six genes (Fig. 4D).
Discussion
ZBED6 is unique to placental mammals and has evolved from a
DNA transposon that integrated into an intron of ZC3H11A in
the genome of a common ancestor of all mammals more than
200 million years ago (6, 13). ZBED6 apparently has evolved an
essential role, because all placental mammals sequenced so far
maintain a well-conserved copy of ZBED6, and the two DNA-
binding domains show 100% sequence identity across species.
Here, for the first time to our knowledge, ZBED6 has been
completely inactivated by genome editing. The expression of
ZC3H11A was not affected by the genome editing, even though
ZBED6 is located in its first intron (6), but ZBED6 protein
expression was abrogated completely. Thus, we can conclude
that the phenotypic effects reported here are caused by the
ZBED6 knock-down. Our results demonstrate that ZBED6 is
not required for cell survival, but its ablation led to consistent
changes in cell growth among three biological replicates of the
same cell lines. However, the phenotypic consequences of
ZBED6 inactivation were strikingly different in the two cell lines:
HCT116 and RKO ZBED6− /− cells showed reduced and
increased growth, respectively. The similarities in growth phe-
notypes observed in the heterozygote clones could indicate (i) a
dominant-negative effect of the targeted allele or (ii) hap-
loinsufficiency of ZBED6. Although a dominant-negative effect
is perhaps less likely, because dimerization is driven by domains
C-terminal of the truncating mutation, haploinsufficiency re-
mains a possible explanation. Furthermore, ZBED6 inactivation
led to substantial changes in RKO and HCT116 transcriptomes,
because the expression of thousands of transcripts was altered
significantly. However, the effects on transcriptional regulation
also differed considerably between the cell lines, both in the
transcripts that showed DE and in the direction of change; only
half of the overlapping DE genes had the same direction of
change in gene expression. These conflicting changes in pheno-
types and transcriptional regulation are consistent with the
emerging view that ZBED6 is a transcriptional modulator that
does not determine whether other genes are active but that in-
teracts with active promoters and fine-tunes the level of gene ex-
pression without recruiting classical silencing mechanisms (14).
Thus, we conclude that the effect of ZBED6 on tumor development
depends on the genetic background and the transcriptional state of
its target genes.
ZBED6 acts as a repressor of IGF2 expression in placental
mammals as demonstrated in pigs used for meat production (6,
11), in mouse C2C12 cells (14), in mouse pancreatic islet cells
(15), and now in human CRC cells. However, the increase in
IGF2 expression after disruption of the binding of ZBED6 to the
intronic IGF2 site in pig skeletal muscle (approximately three-
fold), in C2C12 cells (approximately twofold), and in CRC cells
(1.4- to threefold) is modest compared with the dramatic in-
crease that occurs after differentiation of C2C12 cells (14) or the
250-fold difference in IGF2 expression between RKO and
HCT116 cells. Although IGF2 was barely detectable before
ZBED6 removal from RKO cells, the faster-growing HCT116
cells already had high IGF2 levels. It is possible that IGF2 is not
a limiting factor for these cells and therefore the moderate 1.4-
fold increase after ZBED6 silencing had no impact on cell pro-
liferation. In contrast, the threefold increase in IGF2 expression
in RKO cells could have triggered the increased proliferation.
Given the successful rescue experiment, we propose that the
observed proliferation of RKO cells after ZBED6 ablation is
primarily an effect of increased IGF2 expression. This hypothesis
can be tested experimentally by destroying the ZBED6-binding
site in IGF2 in RKO wild-type cells; the hypothesis predicts that
the effects on cell proliferation should be similar to those ob-
served in the present study in which ZBED6 was inactivated.
Such an experiment also should shed light on how much of the
observed changes in gene expression are secondary effects caused
by increased IGF2 signaling.
Transcriptome analyses showed that one-fifth to one-quarter
of the expressed genes were differentially expressed in ZBED6−/−
cells relative to parental HCT116 and RKO cells. Thus, ZBED6
silencing was associated with substantial changes in the tran-
scriptome, but how many of the DE genes are direct targets for
ZBED6 remains an open question. After combining ChIP-seq and
gene expression analyses, 10 genes that had ZBED6-binding sites
near the TSS and increased expression in ZBED6−/− cells were
selected as putative direct ZBED6 targets and were validated with
qPCR. In qPCR validation experiments, all these genes were up-
regulated in RKO and/or HCT116 ZBED6−/− cells, and the ma-
jority were significantly up-regulated upon siRNA-mediated
knock-down of ZBED6 in HCT116 cells. Strikingly, two—MYBL1
(16) and SPTBN1 (17, 18)—were bona fide cancer genes, and six
genes were linked to pathways involved in CRC: two [ARL4C (19)
and TCF7] to the Wnt pathway, three [ARL4C (19),WWC1/KIBRA
Table 1. Candidate genes for direct ZBED6 targets
Genes
Fold-change
ChIP-seqRKO HCT116
Up-regulated genes
SPTBN1 1.53 2.16 421
COL13A1 4.29 2.08 356
WWC1 1.60 2.27 249
WWTR1 1.62 1.52 192
TCF7 2.00 2.25 140
PMEPA1 2.25 11.96 80
ARL4C 2.99 2.69 73
MYBL1 2.01 2.53 69
FOSL2 1.83 1.91 61
ROCK2 1.52 1.73 59
KCTD1 1.54 1.68 54
MAP3K14 1.56 1.74 48
SGK1 1.73 3.25 43
TUBB3 2.75 1.95 42
MB21D2 1.95 2.30 39
CRIM1 3.20 2.39 36
Down-regulated genes
PPAT 0.60 0.62 300
UPP1 0.04 0.50 62
DDIT4 0.41 0.23 59
ANKRD50 0.29 0.59 33
Genes with at least 1.5-fold change in the same direction in RKO and
HCT116 ZBED6−/− cells and a ChIP-seq peak with at least 30 reads in HCT116.
RNA-seq fold-changes for RKO and HCT116 are given followed by the peak
height of the nearest ZBED6 binding site. The 10 genes selected for valida-
tions are shown in bold.
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(20), and WWTR1/TAZ] to the Hippo pathway, and three [SPTBN1
(21), PMEPA1 (22), and ROCK2 (23)] to the TGF-β pathway. The
Hippo pathway is connected by EGFR signaling to the EGFR
pathway, which is important for CRC growth, through activation of
the Hippo pathway transcription factor Yorkie (24). Thus, apart
from its action on IGF2, ZBED6 can modulate several pathways
essential to CRCs.
In summary, inactivation of ZBED6 in human CRC cells re-
sults in the up-regulation of IGF2 and a subset of other direct
targets of ZBED6 in CRC pathways and altered growth of CRC
cells. The cell systems provided here open new avenues to study
the role of ZBED6 in colorectal tumorigenesis.
Materials and Methods
Gene-Targeting Constructs. To knock out ZBED6, a rAAV gene targeting
construct was designed (i) to mutate Q173 to a stop codon (CAA→TAA), (ii) to
delete the following nucleotide (A), and (iii ) to insert a scar sequence
(LoxP) containing stop codons in several reading frames to ensure loss of
function. The PCR primers used in plasmid construction and integration
screening are listed in Table S2. Left and right homology arms (HAs) were
amplified from genomic DNA of HCT116 with the left HA containing the
Q173 CAA→TAA mutation. Phusion DNA polymerase (Finnzyme) and attB
tailed primers 1–4 were used to amplify the HAs. The PCR conditions were
initial denaturation at 98 °C for 3 min, three cycles of denaturation at 98 °C
for 20 s, annealing at 64 °C for 20 s, and extension at 72 °C for 30 s, followed
by three cycles at 61 °C and 58 °C annealing temperature, respectively. The
final amplification had 25 cycles of denaturation at 98 °C for 20 s, annealing
at 57 °C for 20 s, and extension at 72 °C for 30 s. Next, 100 ng each of the
HA1 and HA2 PCR products was recombined with 150 ng of pDONR P1-P2
and pDONR P3-P4, respectively, using BP Clonase II (11789-020; Invitrogen)
according to the manufacturer’s instructions. The resulting entry clones were
screened for the presence of HAs by colony PCR amplification using Platinum
Taq DNA polymerase (Invitrogen) and M13 primers 5 and 6 flanking the
cloned HAs in the pDONR vectors. The products from the colony PCR for
pEntry-HA1 were sequenced to ensure the presence of the CAA→TAA mu-
tation in the HA1. Next, 10 fmol of each of pEntry-HA1 (harboring Q173* in
HA1), pBUOY.SA.IRES.Neo.pA, and pEntry-HA2 vector were recombined
with 15 fmol of the pAAV-Dest vector using LR Clonase II (Invitrogen)
according to the manufacturer’s instructions. The correct orientation of all
three components in the final targeting construct was confirmed by colony
PCR using LR screening primers 7–10. The AAV293 packaging cell line
(Stratagene) was maintained in DMEM supplemented with 10% FBS and 1%
penicillin-streptomycin (Invitrogen) at 37 °C and 5% CO2. To produce rAAV
particles containing single-stranded targeting DNA, 5 μg of each targeting
construct, pHelper and pRC (Stratagene), was cotransfected into 80% con-
fluent AAV293 cells in a 75-cm2 flask using Lipofectamine (Invitrogen). The
rAAV particles containing the targeting construct were harvested as crude
cellular lysate 48 h after transfection (25).
Knock-Out of ZBED6 in HCT116 and RKO Human CRC Cells. The cell lines HCT116
and RKO were purchased from American Type Tissue Culture Collection. The
cells were maintained in McCoy’s 5A medium supplemented with 10% FBS
and 1% penicillin-streptomycin (Invitrogen) at 37 °C and 5% CO2. Six million
cells were seeded in 75-cm2 flasks, and after 24 h the rAAV.ZBED6 particles
containing lysate were applied directly to the cells in 4 mL of growth me-
dium. Forty-eight hours after infection, the cells were harvested and seeded
into twenty 96-well plates in selection medium containing 450 μg/mL and
800 μg/mL of Geneticin (Invitrogen) for HCT116 and RKO cells, respectively,
at limiting dilution. The cells were selected for 3 wk, and the resulting clones
were screened for site-specific integration of the targeting construct. Each
clone was harvested in 25 μL of trypsin, and 5 μL of cell suspension was
added to 12 μL of Lyse-N-Go reagent (Thermo Scientific). To screen the
clones for site-specific integration, 1 μL of Lyse-N-Go lysate was used in a
Platinum Taq DNA polymerase PCR (20 μL) reaction, using primers 11 and 12.
The PCR products from positive clones were sequenced to confirm the mu-
tation engineering. Three independent positive clones from the first allele
targeting were randomly selected to remove the selection cassette (SA.IRES.
Neo.pA) for each cell line. To excise the selection cassette from the targeted
allele in positive clones, 0.5 million cells were seeded in 25-cm2 flasks, and
107 pfu of Ad-CMV-Cre-GFP (Vector Biolabs) were added to the growth medium.
The cells were incubated for 24 h and then were seeded into 96-well plates at
limiting dilution to get single-cell clones (25). The clones were cultured for 3 wk
and then were screened for removal the of selection cassette using Lyse-N-Go
and primers 13 and 14. The PCR products also were sequenced to confirm the
introduction of the Q173X nonsense mutation in the targeted alleles. Three
independent heterozygous knockout clones with the selection cassette removed
were selected for each cell line. Gene targeting was repeated to knock out the
second wild-type allele.
Real-Time PCR Quantification. Total RNA was extracted from RKO and HCT116
cells using the RNeasy Mini kit (Qiagen), and the samples were treated with
DNase I. The High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems) was used to generate cDNA from the extracted RNA. qPCR analysis
was performed in 384-well ABI MicroAmp Optical Reaction Plates on an ABI
7900 real-time PCR instrument (Applied Biosystems). Forward and reverse
primers (IDT) for each gene were mixed with SYBR Green Gene Expression
Master Mix (Applied Biosystems) in a 10-μL total reaction volume. Primer
sequences are listed in Table S2.
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Fig. 4. Validation of 10 genes bound by ZBED6 and up-regulated in ZBED6−/−
cells. Ten genes up-regulated in both HCT116 and RKO ZBED6−/− cells with a
ZBED6-binding site near the TSS were selected for validation. (A) ChIP-seq
enrichment in one of the candidate genes, ARL4C. (B and C) Validation by
qPCR of expression change in HCT116 and RKO cells. Black bars represent
parental cells; gray bars represent ZBED6−/− cells. (D) Expression of ZBED6
and its target genes after siRNA knockdown of ZBED6 measured by qPCR.
Error bars indicate SD. *P < 0.05; **P < 0.01; ***P < 0.001.
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Immunoblot Analysis. Cells werewashed in PBS and lysed inmodified RIPA lysis
buffer [50 mM Tris·HCl (pH 8.0), 150 mM sodium chloride, 1% Triton X-100,
1 mM EDTA, 0.5% Sodium deoxycholate, 1% SDS] containing protease in-
hibitors (Complete Ultra Tablets; Roche). Lysates were vortexed, incubated
on ice for 15 min, and centrifuged at 10,000 × g for 15 min at 4 °C. The
supernatants were transferred into new tubes, and protein concentrations
were determined by Bradford assay (Dye Reagent; Bio-Rad). Equal amounts
of total lysates were separated by SDS/PAGE gels (4–12%; Bio-Rad) and
transferred into PVDF membranes (Millipore). The membrane was blocked in
SuperBlock blocking buffer (Thermo Scientific) and incubated overnight at
4 °C with primary ZBED6 (1:1,000) (6), ZC3H11A (1:3,000; Abcam), or TATA
binding protein (TBP) (1:5,000; Abcam) antibodies. Thereafter, the mem-
brane was incubated with secondary anti-rabbit IgG or anti-mouse IgG
antibodies conjugated to HRP (1:5,000; Cell Signaling). Proteins were
visualized and detected by chemiluminescence (Amersham ECL Prime De-
tection Reagent; GE Healthcare).
RNA Sequencing. Cells were washed in PBS, and total RNAwas extracted using
the RNeasy Mini kit (QIAGEN). RNA quality and integrity were measured with
an RNA6000Nano Bioanalyzer kit (Agilent Technologies). The MicroPoly(A)Purist
kit (Ambion) was used to enrich for mRNA. Briefly, 4 μg total RNA in binding
buffer was incubated with oligo-dT cellulose at room temperature for
30 min with shaking. Thereafter, the oligo-dT cellulose was washed and
spun down, and the mRNA was eluted in RNA Storage Solution. Strand-
specific RNA sequencing libraries were generated in triplicate for parental
cells and once for each ZBED6−/− clone from HCT116 and RKO cell lines as
described previously (26), but without upper size selection. The libraries
were sequenced as 100-bp paired-end reads using Illumina HiSeq. Sequence
reads were mapped to the reference human genome (hg19) using TopHat
2.0.10 with default parameters. Cuffdiff was used to identify DE genes using
a gene model for hg19 downloaded from the University of California, Santa
Cruz (UCSC) genome browser, and the abundance of gene expression was
calculated as fragments per kilobase of exon per million fragments mapped
(FPKM). For GO analysis, the DE genes were submitted to the Database for
Annotation, Visualization and Integrated Discovery (DAVID) Bioinformatics
Resources 6.7. All expressed genes were used as background, and the
GO_BP_FAT table was used to identify enriched GO terms.
ChIP Sequencing. HCT116 cells were cross-linked with 1% formaldehyde for
10 min, and sonicated chromatin from ∼20 × 106 cells was used for immuno-
precipitation using 2 μg ZBED6 antibody bound to Protein G beads (Dynal).
A barcoded Illumina sequencing library was prepared using NEXTflex adaptors
(BIOO Scientific) and enzymes from New England Biolabs and KAPA. The
library was sequenced using Illumina HiSEq. 2000. The 100-bp single-end reads
were aligned to the hg19 assembly using BWA version 0.5.9 at default settings.
SAMtools was used to remove alignments with low alignment quality (<10),
and the resulting 7.5 million reads were compared with a public HCT116 input
control (ENCODE) using the MACS peak caller (version 1.41) to identify
enriched peaks and to create wiggle tracks for visualization. The 8,892 called
peaks were filtered further to remove peaks in Satellite and rRNA repeats, and
a threshold of a minimum score of 8 (>1 rpm) was applied to give a list of
7,175 ZBED6 peaks.
Silencing of ZBED6. Three Silencer Select siRNAs (Ambion) were used to target
the ZBED6 transcript. The sequences of siRNA oligonucleotides are listed
in Table S3. The three siRNAs were transfected at a final concentration of
100 μM/mL using Lipofectamine 2000 (Invitrogen). After 48 h of incubation, total
RNA was extracted for qPCR quantification as described above. Scrambled
siRNA oligonucleotides were used as control.
Generation of ZBED6 Knockout Clones with Restored Expression of ZBED6. RKO
ZBED6−/− cells were transfected with an AcGFP-Zbed6 fusion construct
(mouse Zbed6 cloned in AcGFP1C1 vector (catalog no. 632470; Clontech),
and pure single-cell expression clones were obtained by flow cytometry. As a
control, AcGFP-expressing ZBED6−/− RKO cells were generated also. Control
and stably transfected cells were lysed as above, separated by SDS/PAGE, and
analyzed by immunoblotting using rabbit polyclonal anti-GFP antibody
(catalog no. NB600-308; Novus Biologicals).
Phenotypic Analyses. For cell growth measurements, 30,000 parental HCT116
and RKO cells along with three ZBED6−/− clones per cell line were seeded in
12-well plates in 10% FBS or 1% FBS, respectively, and were cultured for 13 d
with real-time measurement of cell density every 10–12 h using an IncuCyte
instrument (Essen Bioscience). To assess clonogenicity, 1,000 cells per well of
parental cells, three ZBED6−/− clones, and two ZBED6−/−- AcGFP-Zbed6 clones
were seeded in triplicate in six-well plate wells and cultured in McCoy’s 5A
medium with 10% FBS for 2 wk. The resulting colonies were stained in
methylene blue and counted. Cell-cycle analyses were performed using
FxCycle PI/RNase (LifeTechnologies), and cells were analyzed on an LSRII flow
cytometer (BD).
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